Skip to content Skip to footer

Going beyond symptoms - Treating mental disorders by using data originating in deep brain regions and machine learning

Prism is used by mental health professionals to enhance standard of care clinical outcomes.

Using fMRI data of specific deep brain regions and our proprietary EEG-fMRI machine learning model, Prism delivers EEG neurofeedback to train patients to gain control over biomarkers associated with their mental disorder. 

Prism: Supercharging EEG with fMRI-like capabilities

EEG neurofeedback was considered incapable of measuring deep brain regions, until Prism. 

The unique underlying technology that drives Prism is created in three steps: 

Step 1

A unique data set of fMRI and EEG

Concurrent EEG and fMRI data is acquired from multiple sessions where the fMRI and EEG were synchronized.



Step 2

Brain area-specific EFP (Electrical Fingerprint)

Using a proprietary machine learning model, a unique patient-generic EFP (Electrical Fingerprint) biomarker is created from the synchronized fMRI-EEG data.

Step 3

The Prism system

Prism is an EEG-neurofeedback device (no fMRI needed) used to train patients to regulate the EFP biomarker signal. Therapy includes 15 thirty-minute sessions, conducted twice a week over 8 weeks. Prism is designed to fit at any clinic.

PTSD-first followed by an extensive pipeline

Our first to market solution, Prism –for PTSD, is the first digital therapeutics device for the treatment of PTSD. About 250 million people worldwide live with PTSD, yet treatments are lacking and often lead to many side effects that may last a lifetime.  

Prism for PTSD:  an adjunct to standard of care digital therapeutic currently under multi-center clinical trial in 5 medical centers (Israel and US). Using this product, patients learn to downregulate the amygdala-EFP signal. 

Prism for MDD (Major Depression Disorder): Together with McLean Hospital (the largest psychiatric teaching hospital of Harvard Medical School), GrayMatters Health received a grant from the BIRD foundation to develop a treatment for MDD with anhedonic symptoms, based on EFP biomarker targeting the reward system (Ventral Striatum). 

Prism for ADHD: Exploration phase

Prism for Borderline Personality Disorder: Exploration phase 

Read our publications

Prism’s technology has been extensively published in the most prestigious medical journals, showing significant clinical improvement across multiple indications and no severe side effects, as adjunct to standard of care. 

Studies demonstrated that participants trained with Prism, were able to volitionally downregulate their amygdala activity in post training fMRI 

We are an innovative technology that offers real-time treatment by measuring fMRI-EEG amygdala-EFP biomarkers.

GrayMatters developed an innovative technology that offers real-time treatment by measuring

fMRI-EEG amygdala-EFP biomarkers

PTSD-first followed by an extensive pipeline

Our first to market solution, Prism–for PTSD, is the first digital therapeutics device for the treatment of PTSD. About 250 million people worldwide live with PTSD, yet treatments are lacking and  often lead to many side effects that may last a lifetime.

Prism for PTSD: an adjunct to standard of care digital therapeutic currently under multi-center clinical trial in 5 medical centers (Israel and US) \. Using this product, patients learn to downregulate the amygdala-EFP signal.

Prism for MDD (Major Depression Disorder): Together with McLean Hospital ( the largest psychiatric teaching hospital of Harvard Medical School), GrayMatters Health received a grant from the BIRD foundation to develop a treatment for MDD with anhedonic symptoms, based on EFP biomarker targeting the reward system (Ventral Striatum).

Prism for ADHD: Exploration phase

Prism for Borderline Personality Disorder: Exploration phase

 

 

Read our publications

Prism’s technology has been extensively  published in the most prestigious medical journals, showing significant clinical improvement across multiple indications and no severe side effects, as adjunct to standard of care.

Studies demonstrated that participants trained with Prism, were able to volitionally downregulate their amygdala activity in post training fMRI.

We are an innovative technology that offers real-time treatment by measuring fMRI-EEG amygdala-EFP biomarkers. 

 

Our Team

Prof. Talma Hendler, MD, PhD

Inventor, SAB Chairperson, Chief Medical Scientist

Oded Kraft

co-founder, CEO, President

Rani Cohen

co-founder, Executive chairman, BD

Shai Attia

co-founder, VP R&D

Adar Shani

VP Clinical, Regulatory & Quality Affairs

Tawfik Nasser

Full Stack Developer, R&D team

Dima Lavro, PhD

Algorithm Engineer

Yaki Stern, Ph.D

Algorithm Team Leader

Miriam Feldhamer

QA & Customer Support

Our Partners

Our Partners

Contact Details

Derech HaAtsma'ut 82Haifa

    Go To Top